secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2026-04-02T23:59:59+00:00
Accession:  0001493152-26-014819
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma receives FDA Fast Track designation for norovirus antiviral CDI-988
--------------------------------------------------------------------------------

- FDA granted Fast Track designation for oral, direct-acting protease inhibitor CDI-988 for norovirus.
- CDI-988 is first oral antiviral candidate for both treatment and prophylaxis of norovirus infection.
- Phase 1b double-blind challenge study (NCT07198139) ongoing at Emory University in up to 40 adults.
- Norovirus causes ~685M global infections/year with ~$60B worldwide economic impact.
- Fast Track enables rolling NDA review and potential Priority Review; no financial terms disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315226014819/0001493152-26-014819-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315226014819/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-014819

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer